Tramadol Hydrochnoride as Adjuvant to Local Anesthetic in Ultrasound Guided Erector Spinea Plane Block in Management of Chronic Chest Wall Cancer Pain
Chronic Pain, Erector Spinea Plane Block
About this trial
This is an interventional treatment trial for Chronic Pain focused on measuring chronic chest pain, tramadol hydrochroide, erector spinea plane block
Eligibility Criteria
Inclusion Criteria:
- patients with persistent chronic chest wall cancer pain (>6 months) with VAS pain score ≥ 5 on 0 to 10 scale despite of medical treatment with tramodine up to 200 mg daily
Exclusion Criteria:
- they have hypersensitivity to any of the studied drugs,
- obesity (BMI >35),
- presence of local pathology such as recurrent cancer or infection at the site of injection,
- abnormal coagulation profile,
- an abnormal liver or renal function
- unable to express their pain or
- patient refusal
Sites / Locations
- Assiut UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Placebo Comparator
Active Comparator
Active Comparator
control group
tramadol 50
tramadol 100
patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of NaCl 0.9% will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB
patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 50 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.
patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 100 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.